A patient with aggressive nongerminal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL) receiving the experimental treatment NX-2127 had a complete response at 8 weeks. The response was sustained at 16 weeks and is still being monitored.

These findings were presented at the 5th Annual Targeted Protein Degradation Summit recently held in Boston, Massachusetts.

“To observe a rapid and complete response in a patient with advanced nonGCB DLBCL using a single agent is very gratifying as this subtype of DLBCL is one of the most aggressive and prevalent lymphomas,” said Robert J. Brown, MD, the executive vice president and head of clinical development of Nurix, the developers of the treatment, in a press release.

“We believe that NX-2127, an oral agent with dual activities of degrading [Bruton’s tyrosine kinase (BTK)] and the cereblon neosubstrates Ikaros and Aiolos, may help address the unmet medical need for these patients. We look forward to further exploring the activity of NX-2127 in the ongoing study,” he continued.

Read more about DLBCL

The patient received the experimental drug as part of a phase 1 clinical trial evaluating the safety and anticancer activity of NX-2127 in an estimated 130 patients with advanced B-cell malignancies. Patients were 18 or more years of age.

They received 300 mg of the experimental treatment orally. The complete response included a dramatic reduction in the size of the lymph nodes and the resolution of abnormal metabolic activity to background levels.

The patient also tolerated the treatment well, and the adverse event profile was consistent with previous clinical disclosures.

The trial is still recruiting participants at multiple locations in the US.

NX-2127 is a novel bifunctional molecule that degrades BTK and cereblon neosubstrates Ikaros and Aiolos, which are key drivers of tumor cell proliferation, especially in nonGCB DLBCL.

References

Nurix Therapeutics reports case study of patient with aggressive non-Hodgkin’s lymphoma (NHL) showing a complete clinical response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit. News release. Nurix; October 26, 2022.

A study of NX-2127 in adults with relapsed/refractory B-cell malignancies. US National Library of Medicine. April 2, 2021. Updated September 13, 2022. Accessed November 10, 2022.